Search academic texts

Information × Registration Number 0222U000951, 0119U001070 , R & D reports Title To improve the early diagnosis of metabolic disorders and develop personalized primary prophylactic programs in non-organized population. popup.stage_title Head Isaieva Hanna Serhiivna, Registration Date 21-01-2022 Organization Government Institution "L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine" popup.description2  The study included the results of a survey of 501 patients aged 23 to 79 years (mean age (59,39 ± 1,09) years) with low, moderate and high cardiovascular risk. Patients had their blood pressure (BP) measured, blood pressure monitored daily, body weight, body mass index (BMI), height, fat and muscle tissue ratio assessed, and the risk of developing type 2 diabetes mellitus assessed using the FINDRISK scale, cardiovascular risk was assessed on the following scales: the SCORE scale and the Framingham scale, and the International Long-Term Physical Activity Survey (IPAQ) was used to assess physical activity. The biochemical parameters were evaluated: blood lipids, glucose levels, glycated hemoglobin (HbAlc), uric acid, polymorphisms in PPARG2, ADRB2, ADRB3, FABP2 genes were determined by real-time polymerase chain reaction. In patients with moderate and high cardiovascular risk, carriers of the ADRB2 polymorphic locus (Agr16Glu) are associated with low blood triglycerides, body mass index, glucose, glycosylated hemoglobin, less adipose tissue, and higher muscle strength. The association between the carrier of polymorphic variants CG/SG + GG PPARG2 (Pro12Ala, rs1801282), AA / AA + AG ADRB2 (Arg16Gly, rs1042713) and TT ADRB3 (Trp64Arg, rs4994) and a statistically significant decrease in body mass index, but if the patient is treated with ACE inhibitors or beta-blockers, the value of genetic markers loses its predictor. The combination of the polymorphic variant of the TC ADRB3 gene (Trp64Agr, rs4994) and the AA variant of the ADRB2 gene (Agr16Gly, rs1042713) is associated with a low risk level on the FINDRISK scale, the sensitivity of the test corresponds to 97,2 %. The combination of the AA variant of the ADRB2 gene (Agr16Gly, rs1042713) and the TC or CC variant of the ADRB3 gene (Trp64Agr, rs4994) is a marker of low LDL cholesterol, with a specificity of 97 %. Product Description popup.authors Emelyanova Natalya Isayeva Ganna Babenko Olga Buriakovska Olena Valentinova Inna Vovchenko Maryna Volobuieva Vira Karlashova Taisiia Komir Iryna Kostiuk Olena Nesen Andrii Peteneva Larysa Sydora Inna Chernyshov Volodymyr Shalimova Anna Serhiivna Shkapo Volodimir Shut Inna popup.nrat_date 2022-03-09 Close